U.S., Jan. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07318324) titled 'Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer' on Dec. 29, 2025.
Brief Summary: To find the recommended dose of the combination of avutometinib, defactinib, and everolimus in patients with endometrial cancer that is recurrent and has abnormal RAS activity. The safety and effects of this combination will also be studied.
Study Start Date: June 03, 2026
Study Type: INTERVENTIONAL
Condition:
Phase IB
Avutometinib
RAS Pathway
Endometrial
Intervention:
DRUG: Avutometinib
Given by PO
DRUG: defactinib
Given by PO
DRUG: Everolimus
Given by PO
Recruitment Status: NOT_YET_RECRUI...